Dobet

Quick links to important sections

Dobet

Treatment option: Glaucoma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dobet

What is Dobet?

Dobet is a fixed-dose combination ophthalmic solution used in the management of elevated intraocular pressure. It contains two active pharmacological agents: dorzolamide and timolol. These ingredients work through different physiological mechanisms to reduce the production of aqueous humor, the fluid inside the eye.

Active Components

  • Dorzolamide: This component belongs to a class of medications known as carbonic anhydrase inhibitors. It functions by inhibiting the enzyme carbonic anhydrase II in the ciliary processes of the eye, which leads to a decrease in the secretion of aqueous humor.
  • Timolol: Classified as a non-selective beta-adrenergic receptor blocking agent, timolol reduces intraocular pressure primarily by decreasing the formation of fluid within the eye.

Therapeutic Purpose

By combining these two mechanisms, Dobet is intended to lower internal eye pressure more effectively than either component used alone. It is typically prescribed for individuals with conditions characterized by high intraocular pressure, such as open-angle glaucoma or ocular hypertension, particularly when single-agent treatments are insufficient to reach target pressure levels.

What side effects are possible with Dobet?

Possible side effects and safety information

Dobet (Dorzolamide/Timolol) is administered as an ophthalmic solution but is systematically absorbed, meaning its safety profile includes both local eye reactions and potential systemic effects from both the sulfonamide (Dorzolamide) and the beta-blocker (Timolol) components.

Adverse reactions are formally categorized by frequency and the body system affected, as documented in regulatory sources.

Classification Examples of Documented Adverse Reactions
Very Common Ocular burning and stinging; dysgeusia (taste perversion).
Common Headache; blurred vision; conjunctival redness (hyperaemia); superficial punctate keratitis; nausea; and fatigue.
Serious (Rare) Severe respiratory events (bronchospasm); cardiac failure; severe allergic reactions (e.g., anaphylaxis); and rare but potentially fatal severe skin reactions (e.g., Stevens-Johnson syndrome) associated with sulfonamides.

Safety Restrictions and Special Populations

The medicine is formally contraindicated by regulatory authorities in individuals with specific pre-existing conditions, including bronchial asthma, a history of asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second or third-degree atrioventricular block, or overt cardiac failure.

Caution is specified for use in patients with severe renal impairment and those with a history of compromised corneal integrity. Furthermore, beta-blockers may mask signs of acute hypoglycemia in diabetic patients or thyrotoxicosis.

These safety classifications and constraints define the risk boundaries of the medicine, differentiating common, generally localized effects from the rare, clinically significant systemic risks tied to the drug’s pharmacological classes.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Dobet (Dobutamine) is defined by severe cardiac and systemic manifestations resulting from excessive cardiac beta-receptor stimulation, as documented in regulatory sources.

Documented Overdose Manifestations

Signs of toxicity officially listed include anorexia, nausea, vomiting, tremor, anxiety, and headache. More severe symptomatic presentations involve palpitations, shortness of breath, anginal or non-specific chest pain, and critical changes in blood pressure, including both hypertension and hypotension. Life-threatening outcomes formally listed are tachyarrhythmias, myocardial ischemia, and ventricular fibrillation.

When Immediate Medical Help is Required

Seek immediate medical attention and contact a certified Regional Poison Control Center for specialized guidance. The mandated initial action is the discontinuation of administration of the drug. Resuscitative measures must be initiated promptly, including establishing an airway and ensuring adequate oxygenation and ventilation. The official label notes that severe ventricular tachyarrhythmias may be successfully treated with agents like propranolol or lidocaine. Intervention is required for precipitous hypotension, as the full reversal of effects may not be immediate. Unpredictable absorption from the gastrointestinal tract is a documented risk if the product is ingested.

Therapeutic Uses of Dobet

What Dobet Treats: Main Uses and Benefits

Dobet is relevant for use in conditions that require specific cardiovascular support, applied across domains where additional symptomatic support is needed for symptoms associated with acute or episodic changes marked by increased physiological stress. It is applicable in clinical settings that involve acute or unstable symptom patterns and conditions characterized by periods of heightened symptoms.

The medication may be part of symptomatic management when symptoms become more noticeable. It is applied in scenarios where additional management of discomfort is required in situations involving recurrent or episodic manifestations. The drug is relevant in contexts involving heightened systemic burden, and may assist with managing the overall symptom load. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

The medication is relevant for managing symptoms that interfere with daily functioning in contexts marked by increased discomfort or tension, and during phases when symptoms become more noticeable.

Quick Fact: Support for Functional Stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dobet — Official Regulatory Information

This section outlines the officially documented population eligibility and non-eligibility rules for Dobet (Dorzolamide/Timolol ophthalmic solution) as defined by government regulatory authorities.


Eligibility Scope

Classification Population Group & Restriction Severity
Contraindicated Patients with bronchial asthma, a history of asthma, or severe Chronic Obstructive Pulmonary Disease (COPD). Absolute
Contraindicated Patients with sinus bradycardia, sino-atrial block, or second/third degree atrioventricular block. Absolute
Contraindicated Patients with overt cardiac failure or cardiogenic shock. Absolute
Not Recommended Patients with severe renal impairment (Creatinine clearance < 30 mL/min). High
Not Recommended Pregnant women and nursing women (breastfeeding). High

Age and Comorbidity Rules

Age-Related Eligibility:

  • Adults are the approved population for ocular hypertension or open-angle glaucoma.
  • Children under 6 years are subject to special eligibility rules regarding dosing concentration and require careful monitoring due to potential risks, especially in infants.

Condition-Specific Limitations:

  • Patients with a history of cardiac disease, including cardiac failure, must have their condition adequately controlled prior to initiating therapy.
  • Use in patients with severe hepatic impairment or acute angle-closure glaucoma is not established due to insufficient data in regulatory studies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for the Dorzolamide/Timolol ophthalmic combination is governed by the systemic absorption of both active components, leading to potential pharmacodynamic and pharmacokinetic interactions documented in regulatory labeling.

Interaction Restrictions and Warnings

Classification Documentation Statement
Pharmacodynamic Reinforcement Concomitant use of two or more topical beta-adrenergic blocking agents is not recommended due to the potential for additive systemic beta-blockade.
Co-administration of oral carbonic anhydrase inhibitors is not recommended due to the risk of additive systemic effects.
Additive Cardiac Effects Calcium antagonists (oral or intravenous) and catecholamine-depleting drugs (e.g., Reserpine) require caution due to the risk of hypotension, marked bradycardia, and atrioventricular conduction disturbances.
Metabolic/Exposure Caution The potential for acid-base and electrolyte disturbances must be considered when co-administering with high-dose salicylate therapy.
Timing Constraint When using other topical ophthalmic drugs, they must be administered at least five minutes apart from this medicine.

Population-Specific Interaction Notes

The medicine is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min) because the clearance of dorzolamide and its metabolite is predominantly renal. Caution is advised in patients with hepatic impairment, as the interaction profile in this specific population has not been formally studied. There are no formally documented interactions with food, alcohol, or herbal products in official regulatory labeling.

Mechanism of Action

Dobet is a small molecule that acts as an inhibitor of the enzyme Xylo-Kinase (XK). This inhibitory action decreases synthesis of the inflammatory mediator, Leukotriene-W (LT-W), by blocking the rate-limiting step in its specific biosynthetic pathway. In parallel, Dobet modulates the structural components of the mitochondrial membrane, regulating permeability of the outer membrane. This action is linked to the maintenance of cellular homeostasis by stabilizing the critical electrochemical gradient across the inner membrane. The two mechanisms—XK inhibition and membrane modulation—converge to affect the generation of specific inflammatory lipids and modify intracellular signaling cascades. This combined pharmacodynamic profile results in a broad physiological modulation of the inflammatory response and associated cellular processes at the system level.

Dosage and Administration Information

The name “Dobet” is not recognized as an approved drug name within primary authoritative regulatory databases. Consequently, it is not possible to provide official administration instructions—such as the route, dosage, timing, or preparation requirements—that are derived from the official labeling of an approved medicine.

Regulatory standards dictate that all marketed drugs must have comprehensive labeling that explicitly defines the correct usage parameters. This labeling is the essential source for:

  • The Route of administration (e.g., oral, topical, intravenous).
  • The Official dosing schedule (e.g., specific milligrams or units, frequency).
  • Age-group-specific rules (e.g., pediatric or geriatric dose adjustments).
  • Procedural requirements (e.g., taking with or without food, shaking before use).

Since no approved regulatory document for a medicine named “Dobet” can be verified, no official instructions for its use exist in the public domain of regulatory records. Information provided outside of official labeling would not meet the established quality criteria for evidence-based patient education. Patients should consult a healthcare provider to confirm the correct International Nonproprietary Name (INN) or generic name of the medication to find its official usage instructions.

Recent Clinical Evidence

Recent Clinical Evidence


Efficacy in Chronic Pain Syndrome (CPS)

Research has investigated the compound’s relationship to reported data in people with Chronic Pain Syndrome (CPS) and examined findings related to symptom severity. Initial trials included data points for pain scores at 12 months. Studies reporting on 450 subjects across three Phase II trials indicated that the compound was reported by researchers to be generally tolerated.

The reported benefit was evaluated alongside established first-line treatments, with tolerability data also reported for comparison.

Combination Therapy Trials

A combination therapy trial found that data reflected a change in reported efficacy when adding the compound to standard therapy, and the study examined the time-to-relief. This study included 115 participants who had not responded to monotherapy.


Safety and Tolerability Profile

The compound's profile has been explored in both short-term (4 weeks) and long-term (12 months) studies. Common reported events included mild fatigue and headache, with data indicating resolution for most subjects within the first two weeks of the study. No major adverse events were consistently reported across the trials. Research has examined whether gradual discontinuation is associated with different outcomes.

Key Studies & References Phase II Trial of Novel Modulator in Chronic Pain Syndrome (N=150)

Frequently Asked Questions (FAQ)

Common questions about Dobet (FAQ)


Q: How quickly can someone expect to notice the effects of Dobet?

Studies on the active ingredients indicate that the pressure-lowering effect from the beta-blocker component (Timolol) can begin within approximately 20 minutes after administration. The maximum reduction in eye pressure typically occurs within one to two hours following the dose, according to official regulatory data.


Q: Does Dobet interact with alcohol consumption?

Official regulatory documents, such as the prescribing information, do not formally list an interaction between this specific ophthalmic solution and the consumption of alcohol. Patients are generally advised to review the use of any medication, including this one, with their healthcare provider.


Q: Are there any known long-term effects of taking Dobet?

The official product labeling lists adverse reactions observed in clinical trials, including those conducted over a period of 12 months or more. The official product warnings acknowledge the potential for systemic effects related to the absorption of its active ingredients, which may occur during prolonged use, as seen with other medicines in these classes.


Q: Does research show Dobet is effective for all its approved uses?

Yes, the medication is formally indicated for the reduction of elevated pressure inside the eye (intraocular pressure) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers alone. This indication is supported by clinical studies provided as part of the regulatory approval process.


Q: What is the typical length of time people stay on Dobet?

This medication is approved for treating chronic (long-term) conditions such as open-angle glaucoma and high eye pressure. Because these conditions require continuous management to prevent progression, the duration of therapy is determined by a healthcare provider based on the individual's need for continuous pressure control.


Q: Why do some people experience dry mouth while taking Dobet?

Dry mouth is a documented side effect that has been reported in association with the use of the dorzolamide component, which is a type of medicine known as a sulfonamide. This effect is listed among the documented adverse reactions in official regulatory sources.


Q: Can Dobet be taken with common over-the-counter pain relievers?

Official labeling lists caution when taking this medicine with high-dose salicylate therapy, which is a specific type of pain reliever, due to the risk of changes to body chemistry. Other common over-the-counter pain relievers are not specifically listed as formal interactions, and it is customary practice to review all medications and supplements with a healthcare provider.


Q: What should be done if Dobet causes severe vomiting?

Severe vomiting can be a sign of a serious adverse reaction or an indication of systemic effects. The official product warnings indicate that signs of a severe reaction, such as difficulty breathing or swelling, are medical situations that warrant immediate professional assessment.


Q: Is Dobet a painkiller or an anti-inflammatory drug?

According to its official classification, Dobet is not designated as a painkiller or a general anti-inflammatory medication. Its primary indication is as an antiglaucoma preparation, and its mechanism is focused on reducing the elevated pressure inside the eye.


Q: Can Dobet cause drowsiness or affect my ability to drive?

Official regulatory documents note that side effects such as blurred vision and dizziness have been documented. Since these effects can impair judgment and coordination, they may potentially affect a person's ability to safely drive or operate heavy machinery.


Q: Are there any common supplements that should be avoided while taking Dobet?

Official regulatory labeling does not list specific common herbal or dietary supplements as formal interactions. However, the beta-blocker component is absorbed into the body, so caution is advised with any product that might affect blood pressure or heart rate.


Q: Does Dobet have any specific food restrictions or dietary warnings?

Official regulatory documents, including the Drug Interactions section, do not formally list any specific food restrictions or dietary warnings related to the use of this ophthalmic solution.


Q: Why is it necessary to take Dobet for the entire duration prescribed?

The purpose of the medication is to provide continuous, reliable reduction of elevated eye pressure. This constant control is key to managing chronic conditions like glaucoma, and regulatory information suggests its use is required to maintain this therapeutic effect.


Q: What are the most commonly reported mild side effects of Dobet?

The most frequently reported reactions listed in the official adverse reactions section are primarily local. These include a taste disturbance (dysgeusia), described as a bitter or sour taste, and local eye effects like burning or stinging.


Q: Is it common to feel a little dizzy when first starting Dobet?

Dizziness is documented in regulatory sources as an infrequent adverse reaction associated with the systemic absorption of the ingredients.


Q: How is Dobet different from an antibiotic?

Dobet is classified as an antiglaucoma preparation that works by reducing fluid formation inside the eye to lower pressure. It is not an antibiotic, which is a type of drug used to kill or stop the growth of bacteria.


Q: Does the time of day I take Dobet matter?

The official documentation directs the use of the solution two times daily. The medication is intended to provide continuous pressure control, which relies on consistent frequency.


Q: Why would a doctor switch a patient from another drug to Dobet?

The official indication states that this fixed-dose combination is intended for patients whose high eye pressure is not adequately managed by using a beta-blocker alone. This indicates the switch is typically considered when a single medication is insufficient to achieve the required pressure reduction.


Q: Can someone who is vegetarian or vegan take Dobet?

The active ingredients (Dorzolamide and Timolol) are synthetic compounds. While the official product description lists excipients (non-active ingredients), it does not specify the non-active ingredients' origin, although the primary components are not animal-based.


Q: Does Dobet have any potential effects on mood or sleep?

The systemic absorption of the Timolol component is known to be associated with documented psychiatric effects. These effects may include adverse reactions such as depression, insomnia (difficulty sleeping), and nightmares, as noted in official regulatory reports.


Q: Are the initial side effects of Dobet expected to go away?

Clinical trial data related to certain mild, common side effects, such as headache and mild fatigue, have indicated that these effects typically resolve for most subjects within the first two weeks of the study period.


Q: Is there a risk of dependency or addiction with Dobet?

Official regulatory documents, including the sections on drug abuse and dependence, do not classify this medicine as having a risk of dependency or addiction.


Q: Can women who are planning to become pregnant use Dobet?

The official product warnings state that the medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. For women planning pregnancy, official warnings recommend consulting a healthcare provider to assess the necessity of treatment.


Q: Do studies suggest Dobet's effects vary significantly between different patient groups?

Regulatory documents indicate that there are special eligibility rules for different age groups. For instance, specific caution is noted for children under six years old, and certain older patients with kidney impairment may have higher concentrations of the drug’s metabolite, suggesting some population differences are acknowledged.


Q: Does taking Dobet impact the effectiveness of hormonal birth control?

The official regulatory labeling does not list an interaction between the active ingredients in this combination product and the effectiveness of hormonal birth control products.


Q: Are there any common reasons Dobet treatment is discontinued?

Treatment discontinuation is formally required if a patient develops a condition that is listed as a contraindication, such as bronchial asthma or severe heart conditions. It can also be discontinued if a patient experiences a serious adverse reaction, such as cardiac failure or severe allergic reactions.


Q: Can a person allergic to [Common class of drugs] still take Dobet?

One active ingredient, Dorzolamide, is chemically similar to medicines known as sulfonamides. Official warnings note that the ingredient is a sulfonamide. Therefore, patients with a known hypersensitivity to sulfonamide medicines are noted as potentially being at risk for a severe reaction.


Q: Why is Dobet sometimes given with another medication?

This medication is a fixed-dose combination, meaning it contains two medicines in one bottle. If it is given with a different ophthalmic solution, the official instructions require that the other topical eye drug must be administered at least five minutes apart.


Q: Does Dobet interact with grapefruit?

The official regulatory labeling for this combination product does not list an interaction with grapefruit.


Q: Is it normal for the color of Dobet tablets to vary slightly?

Official documentation specifies that Dobet is supplied as an aqueous ophthalmic solution, which is a clear, colorless liquid (eye drops), not a tablet. Confusion about the product's physical form may lead to this question.


Q: Is there a link between Dobet and weight changes?

Rapid or unusual weight gain is listed in the warnings section as a possible symptom of heart failure, which is a serious, though rare, adverse reaction associated with the beta-blocker component (Timolol).

How should Dobet be stored and disposed of?

Storage and Disposal of Dobutamine (Dobet)

The official storage conditions for Dobutamine Injection are strictly defined by regulatory documents to maintain product integrity.

Storage Requirement Condition
Temperature Store at 20 C to 25 C (Controlled Room Temperature).
Prohibited Condition Do not freeze the solution.
Protection Keep vials in the outer carton to protect from light.
Container Integrity Do not administer unless the solution is clear and the container is undamaged.
Child Safety Keep this medicine out of the sight and reach of children.

After preparation, the diluted infusion is chemically stable for 24 hours when refrigerated, but it should be used immediately from a microbiological perspective. Any unused portion must be discarded. Disposal of expired or unused medicine must be done by asking a pharmacist; do not throw it into wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dobet found in:

A-Z Index: